Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine
Study Identifier:
D7841C00012
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Vemircopan
- Drug: Rosuvastatin
- Drug: Metformin
- Drug: Levonorgestrel / Ethinyl Estradiol
- Drug: Carbamazepine
Date
Jan 2024 - Apr 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years
Requirements Information
Sex
Female & Male
Age
18 - 55 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Vemircopan
- Drug: Rosuvastatin
- Drug: Metformin
- Drug: Levonorgestrel / Ethinyl Estradiol
- Drug: Carbamazepine
Date
Jan 2024 - Apr 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years years
Requirements Information
Protocol Summary
This study will investigate the potential drug interactions between vemircopan and metformin, rosuvastatin, levonorgestrel/ ethinyl estradiol (LNG/EE)-containing oral contraceptive(s) (OCs), and carbamazepine in healthy participants.
Trial Locations
Location
Status
Location
Research Site
Brooklyn, Maryland, United States, 21225
Status
N/A